RNLX.Y Stock Overview
Develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Renalytix Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.17 |
| 52 Week High | UK£2.40 |
| 52 Week Low | UK£0.12 |
| Beta | 2.1 |
| 11 Month Change | -35.87% |
| 3 Month Change | -62.69% |
| 1 Year Change | -83.86% |
| 33 Year Change | -99.33% |
| 5 Year Change | n/a |
| Change since IPO | -98.76% |
Recent News & Updates
Recent updates
Renalytix: The Investment Case Is Shot
Jul 25Renalytix AI GAAP EPS of -$0.20, revenue of $0.81M
Jun 30Renalytix: High Growth Artificial Intelligence Play, Nearing A Possible Breakout
Apr 05Renalytix: Laying The Foundations For Growth
Jan 05Renalytix: Building Out A Capability To Ramp Revenue
Oct 20Renalytix AI EPS beats by $0.06, misses on revenue
Jun 15Centers for Medicaid & Medicare establishes MICT pathway
Jan 13Exact and Exact Sciences trade higher; Seen as beneficiaries from new CMS rule
Jan 12Shareholder Returns
| RNLX.Y | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 11.7% | -3.0% | -0.4% |
| 1Y | -83.9% | 7.6% | 39.5% |
Return vs Industry: RNLX.Y underperformed the US Healthcare Services industry which returned 7.6% over the past year.
Return vs Market: RNLX.Y underperformed the US Market which returned 39.5% over the past year.
Price Volatility
| RNLX.Y volatility | |
|---|---|
| RNLX.Y Average Weekly Movement | 15.6% |
| Healthcare Services Industry Average Movement | 10.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RNLX.Y's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: RNLX.Y's weekly volatility has decreased from 41% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | James McCullough | renalytix.com |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Renalytix Plc Fundamentals Summary
| RNLX.Y fundamental statistics | |
|---|---|
| Market cap | US$19.76m |
| Earnings (TTM) | -US$33.46m |
| Revenue (TTM) | US$2.29m |
8.6x
P/S Ratio-0.6x
P/E RatioIs RNLX.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RNLX.Y income statement (TTM) | |
|---|---|
| Revenue | US$2.29m |
| Cost of Revenue | US$2.13m |
| Gross Profit | US$156.00k |
| Other Expenses | US$33.61m |
| Earnings | -US$33.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 6.82% |
| Net Profit Margin | -1,461.60% |
| Debt/Equity Ratio | -108.1% |
How did RNLX.Y perform over the long term?
See historical performance and comparison